Established and novel biomarkers of sepsis

Biomarkers in Medicine

Volumn 5, Issue 2, 2011, Pages 117-130

  Faix, James D ^a  

^a STANFORD UNIVERSITY   (United States)

Author keywords

C reactive protein; CD64; cytokines; immunoregulation; lactaten procalcitonin; sepsis

Indexed keywords

ACUTE PHASE PROTEIN; ANTIBIOTIC AGENT; BACTERIAL ANTIGEN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CD64 ANTIGEN; COMPLEMENT COMPONENT C5A; CORTICOSTEROID; CYTOKINE; D DIMER; DROTRECOGIN; ENDOTOXIN; GLUCOCORTICOID; HEPARIN BINDING PROTEIN; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 6; INTERLEUKIN 8; LACTIC ACID; LIPOPOLYSACCHARIDE BINDING PROTEIN; MONOCYTE CHEMOTACTIC PROTEIN 1; PENTRAXIN 3; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROCALCITONIN; PROTEIN C; TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 1; TUMOR NECROSIS FACTOR;

BACTERIAL INFECTION; DISEASE ASSOCIATION; DISEASE COURSE; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG MEGADOSE; GENE EXPRESSION PROFILING; GRAM NEGATIVE SEPSIS; HIGH RISK PATIENT; HUMAN; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; LACTATE BLOOD LEVEL; LEUKOCYTE ACTIVATION; LOW DRUG DOSE; MEMBRANE MICROPARTICLE; MORTALITY; MULTIPLE MYELOMA; NONHUMAN; OUTCOME ASSESSMENT; PATHOGENESIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; RHEUMATIC DISEASE; SEPSIS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

BIOLOGICAL MARKERS; GENE EXPRESSION PROFILING; HUMANS; IMMUNITY, INNATE; IMMUNOSUPPRESSION; INFLAMMATION; NEUTROPHIL ACTIVATION; SEPSIS;

EID: 79953872594     PISSN: 17520363     EISSN: None     Source Type: Journal    
DOI: 10.2217/bmm.11.21     Document Type: Review

References (80)

1. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: Defnitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit. Care Med. 20, 864-874 (1992).
2. Levy MM, Fink MP, Marshall JC et al.: 2001 SCCM/ESICM/ATS/SIS International Sepsis Defnitions Conference. Crit. Care Med. 31, 1250-1256 (2003). (Pubitemid 36444440)
3. Levy MM, Dellinger RP, Townsend SR et al.: The surviving sepsis campaign: results of an international guideline-based performance improvement program targeting severe sepsis. Crit. Care Med. 38, 367-374 (2010).
4. Finfer S: Corticosteroids in septic shock. N. Engl. J. Med. 358, 188-190 (2003).
5. Stearns-Kurosawa DJ, Osuchowski MF, Valentine C, Kurosawa S, Remick DG: Pathogenesis of sepsis. Ann. Rev. Pathol. Mech. Dis. 6, 19-48 (2011).
6. Hotchkiss RS, Karl IE: The pathophysiology and treatment of sepsis. N. Engl. J. Med. 348, 138-150 (2003). (Pubitemid 36056721)
7. Monneret G, Lepape A, Voirin N et al.: Persisting low monocyte human leukocyte antigen-DR expression predicts mortality in septic shock. Intensive Care Med. 32, 1175-1183 (2006). (Pubitemid 44232412)
8. Rivers E, Nguyen B, Havstad S et al.: Early goal-directed therapy in the treatment of severe sepsis and septic shock. N. Engl. J. Med. 345, 1368-1377 (2001).
9. Marshall JC, Reinhart K: Biomarkers of sepsis. Crit. Care Med. 37, 2290-2298 (2009).
10. Salluh JIF, Bozza PT: Biomarkers of sepsis: lost in translation? Crit. Care Med. 36, 2192-2194 (2008).
11. Pierrakos C, Vincent JL: Sepsis biomarkers: a review. Crit. Care 14, R15 (2010).
12. Abbas AK, Lichtman AH, Pillai S: Cytokines. In: Cellular and Molecular Immunology (6th Edition). Abbas AK, Lichtman AH, Pillai S (Eds). Saunders Elsevier Publishers, PA, USA, 237-301 (2010).
13. Abbas AK, Lichtman AH, Pillai S: Innate immunity. In: Cellular and Molecular Immunology (6th Edition). Abbas AK, Lichtman AH, Pillai S (Eds). Saunders Elsevier Publishers, PA, USA, 19-46 (2010).
14. Gabay C, Kushner I: Acute-phase proteins and other systemic responses to infammation. N. Engl. J. Med. 340, 448-454 (1999). (Pubitemid 29084777)
15. Ghezzi P, Cerami A: Tumor necrosis factor as a pharmacological target. Methods Mol. Med. 98, 1-8 (2004).
16. Bozza FA, Salluh JI, Japiassu AM et al.: Cytokine profles as markers of disease severity in sepsis: a multiplex analysis. Crit. Care 11, R49 (2007).
17. Nishimoto N: Interleukin-6 as a therapeutic target in candidate infammatory diseases. Clin. Pharmacol. Ther. 87, 483-487 (2010).
18. Osuchowski MF, Connett J, Welch K et al.: Stratifcation is the key: infammatory biomarkers accurately direct immunomodulatory therapy in experimental sepsis. Crit. Care Med. 37, 1567-1573 (2009).
19. Lamontagne F, Briel M, Duffett M et al.: Systematic review of reviews including animal studies addressing therapeutic interventions for sepsis. Crit. Care Med. 38, 2401-2408 (2010).
20. Eliasson M, Egesten A: Antibacterial chemokines: actors in both innate and adaptive immunity. In: Trends in Innate Immunity. Egesten A, Schmidt A, Herwald H (Eds). Karger, Basel, Switzerland, 101-117 (2008).
21. Stryjewski GR, Nylen ES, Bell MJ et al.: Interleukin-6, interleukin-8, and a rapid and sensitive assay for calcitonin precursors for the determination of bacterial sepsis in febrile neutropenic children. Pediatr. Crit. Care Med. 6, 129-135 (2005). (Pubitemid 40724303)
22. Manfredi AA, Rovere-Querini P, Bottazzi B et al.: Pentraxins, humoral immunity and tissue injury. Curr. Opin. Immunol. 20, 538-544 (2008).
23. Assicot M, Gendrel D: High serum procalcitonin concentrations in patients with sepsis and infection. Lancet 341, 515-518 (1993). (Pubitemid 23066085)
24. Muller B, White JC, Nylen ES et al.: Ubiquitous expression of the calcitonin-I gene in multiple tissues in response to sepsis. J. Clin. Endocrinol. Metab. 86, 396-404 (2001). (Pubitemid 32109825)
25. Karzai W, Oberhoffer M, Meier-Hellmann A, Reinhart K: Procalcitonin: a new indicator of the systemic response to severe infections. Infection 25, 329-334 (1997). (Pubitemid 27507299)
26. Tavares E, Minano FJ: Immunoneutralization of the aminoprocalcitonin peptide of procalcitonin protects rats from lethal endotoxaemias: neuroendocrine and systemic studies. Clin. Sci. 119, 519-534 (2010).
27. Simon L, Gauvin F, Amre DK et al.: Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis. Clin. Inf. Dis. 39, 206-217 (2004). (Pubitemid 38971491)
28. Uzzan B, Cohen R, Nicolas P et al.: Procalcitonin as a diagnostic test for sepsis in critically ill adults and after surgery or trauma: a systematic review and meta-analysis. Crit. Care Med. 34, 1996-2003 (2006). (Pubitemid 43982479)
29. Becker KL, Snider R, Nylen ES: Procalcitonin assay in systemic infammation, infection, and sepsis: clinical utility and limitations. Crit. Care Med. 36, 941-952 (2008).
30. Billeter A, Turina M, Seifert B et al.: Early serum procalcitonin, interleukin-6, and 24-hour lactate clearance: useful indicators of septic infections in severely traumatized patients. World J. Surg 33, 558-566 (2009).
31. Ammori BJ, Becker KL, Kite P et al.: Calcitonin precursors: early markers of gut barrier dysfunction in patients with acute pancreatitis. Pancreas 27, 239-243 (2003). (Pubitemid 37205871)
32. Clec'h C, Fosse JP, Karoubi P et al.: Differential diagnostic value of procalcitonin in surgical and medical patients with septic shock. Crit. Care Med. 34, 102-107 (2006). (Pubitemid 43032386)
33. Jensen JU, Heslet L, Jensen TH et al.: Procalcitonin increase in early identifcation of critically ill patients at high risk of mortality. Crit. Care Med. 34, 2596-2602 (2006). (Pubitemid 44413058)
34. Bouadma L, Luyt CE, Tubach F et al.: Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomized controlled trial. Lancet 375, 463-474 (2010).
35. Mauri T, Bellani G, Patroniti N: Persisting high levels of plasma pentraxin 3 over the frst days after severe sepsis and septic shock onset are associated with mortality. Intensive Care Med. 36, 621-629 (2010).
36. Gutsmann T, Mueller M, Carroll SF et al.: Dual role of lipopolysaccharide (LPS)-binding protein in neutralization of LPS and enhancement of LPS-induced activation of mononuclear cells. Infect. Immun. 69, 6942-6950 (2001). (Pubitemid 32995454)
37. Sakr Y, Burgett U, Nacul FE et al.: Lipopolysaccharide-binding protein in a surgical intensive care unit: a marker of sepsis? Crit. Care Med. 36, 2014-2022 (2008).
38. Flierl MA, Rittirsch D, Nadeau BA et al.: Functions of the complement components C3 and C5 during sepsis. FASEB J. 22, 3483-3490 (2008).
39. Schreiber H, Rittirsch D, Flieri M et al.: Complement activation during sepsis in humans. Adv. Exp. Med. Biol. 586, 217-226 (2006).
40. Leino L, Sorvajarvi L, Katajisto M et al.: Febrile infection changes the expression of IgG Fc receptors in human neutrophils in vivo. Clin. Exp. Immunol. 107, 37-43 (1997). (Pubitemid 27019808)
41. Bhandari V, Wang C, Rinder C, Rinder H: Hematologic profle of sepsis in neonates: neutrophil CD64 as a diagnostic marker. Pediatrics 121, 129-134 (2008).
42. Davis BH, Olsen SH, Ahmad E, Bigelow NC: Neutrophil CD64 is an improved indicator of infection or sepsis in emergency department patients. Arch. Pathol. Lab. Med. 130, 654-661 (2006). (Pubitemid 43736869)
43. Icardi M, Erickson Y, Kilborn S et al.: CD64 index provides simple and predictive testing for detection and monitoring of sepsis and bacterial infection in hospital patients. J. Clin. Micro. 47, 3914-3919 (2009).
44. Elghetany M, Davis B: Impact of preanalytical variables on granulocytic surface antigen expression: a review. Cytometry 65, 1-5 (2005). (Pubitemid 40617005)
45. Bouchon A, Facchetti F, Weigand MA et al.: TREM-1 amplifes infammation and is a crucial mediator of septic shock. Nature 410, 1103-1107 (2001). (Pubitemid 32391042)
46. Gibot S, Cravoisy A, Dupays R et al.: Combined measurement of procalcitonin and soluble TREM-1 in the diagnosis of nosocomial sepsis. Scand. J. Infect. Dis. 39, 604-608 (2007). (Pubitemid 47009172)
47. Bopp C, Hofer S, Bouchon A et al.: Soluble TREM-1 is not suitable for distinguishing between systemic infammatory response syndrome and sepsis survivors and nonsurvivors in the early stage of acute infammation. Eur. J. Anaesthesiology 26, 504-507 (2009).
48. Gautam N, Olofsson AM, Herwald H et al.: Heparin-binding protein (HBP/CAP37): a missing link in neutrophil-evoked alteration of vascular permeability. Nat. Med. 7, 1123-1127 (2001). (Pubitemid 33010020)
49. Linder A, Christensson B, Herwald H et al.: Heparin-binding protein: an early marker of circulatory failure in sepsis. Clin. Inf. Dis. 49, 1044-1050 (2009).
50. Esmon CT: Interactions between the innate immune and blood coagulation systems. Trends Immunol. 25, 536-542 (2004). (Pubitemid 39208352)
51. Dhainaut JF, Shorr AF, Macias WL et al.: Dynamic evolution of coagulopathy in the frst day of severe sepsis: relationship with mortality and organ failure. Crit. Care Med. 33, 341-348 (2005). (Pubitemid 40216547)
52. Taylor FB, Toh CH, Hoots WK et al.: Towards defnition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb. Haemost. 86, 1327-1330 (2001).
53. Voves C, Wuillemin WA, Zeerleder S: International Society on Thrombosis and Hemostasis score for overt disseminated intravascular coagulation predicts organ dysfunction and fatality in sepsis patients. Blood Coagul. Fibrinolysis 17, 445-451 (2006). (Pubitemid 44231689)
54. Toussaint S, Gerlach H: Activated protein C for sepsis. N. Engl. J. Med. 361, 2646-2652 (2009).
55. Shorr AF, Nelson DR, Wyncoll DLA et al.: Protein C: a potential biomarker in severe sepsis and a possible tool for monitoring treatment with drotrecogin-α (activated). Crit. Care 12, R45 (2008).
56. Zakariah AN, Cozzi SM, Van Nuffelen M et al.: Combination of biphasic transmittance waveform with blood procalcitonin levels for diagnosis of sepsis in acutely ill patients. Crit. Care Med. 36, 1507-1512 (2008). (Pubitemid 351620658)
57. Adamzik M, Eggman M, Frey UH et al.: Comparison of thromboelastometry with procalcitonin, interleukin-6, and C-reactive protein as diagnostic tests for severe sepsis in critically ill adults. Crit. Care 14, R178 (2010).
58. Toffaletti JG: Blood lactate: biochemistry, laboratory methods, and clinical interpretation. Crit. Rev. Clin. Lab. Sci. 28, 253-268 (1991).
59. + ATPase activity and raised lactate concentration in septic shock: a prospective study. Lancet 365, 871-875 (2005). (Pubitemid 40332165)
60. Mikkelsen ME, Miltiades AN, Gaieski DF et al.: Serum lactate is associated with mortality in severe sepsis independent of organ failure or shock. Crit. Care Med. 37, 1670-1677 (2009).
61. Cocucci E, Racchetti G, Meldolesi J: Shedding vesicles: artefacts no more. Trends Cell Biol. 19, 43-51 (2009).
62. Meziani F, Delabranche X, Asfar P, Toti F: Bench-to-bedside review: circulating microparticles-a new player in sepsis? Crit. Care 14, 236 (2010).
63. Tang BMP, McLean AS, Dawes IW et al.: The use of gene-expression profling to identify candidate genes in human sepsis. Am. J. Respir. Care Med. 176, 676-684 (2007). (Pubitemid 47503075)
64. Tang BMP, McLean AS, Dawes IW et al.: Gene-expression profling of peripheral blood mononuclear cells in sepsis. Crit. Care Med. 37, 882-888 (2009).
65. Tang BMP, McLean AS, Dawes IW et al.: Gene-expression profling of Gram-positive and Gram-negative sepsis in critically ill patients. Crit. Care Med. 36, 1125-1128 (2008). (Pubitemid 351482660)
66. Wong HR, Cvijanovich N, Allen GL et al.: Genomic expression profling across the pediatric systemic infammatory response syndrome, sepsis, and septic shock spectrum. Crit. Care Med. 27, 1558-1566 (2009).
67. Zeitoun AAH, Gad SS, Attia FM, Maziad ASA, Bell EF: Evaluation of neutrophilic CD64, interleukin-10 and procalcitonin as diagnostic markers of early-and late-onset neonatal sepsis. Scand. J. Inf. Dis. 42, 299-305 (2010).
68. Weiss M, Schneider EM: Soluble CD163: an age-dependent, anti-infammatory biomarker predicting outcome in sepsis? Crit. Care Med. 34, 2682-2683 (2006). (Pubitemid 44413075)
69. Saukkonen K, Lakkisto P, Pettila V et al.: Cell-free plasma DNA as a predictor of outcome in severe sepsis and septic shock. Clin. Chem. 54, 1000-1007 (2008). (Pubitemid 351793406)
70. Moreira VG, Prieto B, Rodriguez JSM, Alvarez FV: Usefulness of cell-free plasma DNA, procalcitonin and C-reactive protein as markers of infection in febrile patients. Ann. Clin. Biochem. 47, 253-258 (2010).
71. Cheron A, Floccard B, Allaouchiche B et al.: Lack of recovery in monocyte human leukocyte antigen-DR expression is independently associated with the development of sepsis after major trauma. Crit. Care 14, R208 (2010).
72. Abbas AK, Lichtman AH, Pillai S: Immunological tolerance. In: Cellular and Molecular Immunology (6th Edition). Abbas AK, Lichtman AH, Pillai S (Eds). Saunders Elsevier Publishers, PA, USA, 243-263 (2010).
73. Roger PM, Hyvernat H, Breittmayer JP et al.: Enhanced T-cell apoptosis in human septic shock is associated with alteration of the costimulatory pathway. Eur. J. Clin. Microbiol. Infect. Dis. 28, 575-584 (2009).
74. Nizet V: Understanding how leading bacterial pathogens subvert innate immunity to reveal novel therapeutic targets. J. Allergy Clin. Immunol. 120, 13-22 (2007). (Pubitemid 46990514)
75. Pene F, Courtine E, Cariou A, Mira JP: Toward theragnostics. Crit. Care Med. 37, S50-S58 (2009).
76. Becker KL, Snider R, Nylen ES: Procalcitonin in sepsis and systemic infammation: a harmful biomarker and a therapeutic target. Br. J. Pharmacol. 159, 253-264 (2010).
77. Ward PA: Sepsis, apoptosis and complement. Biochem. Pharmacol. 76, 1383-1388 (2008).
78. Huang X, Venet F, Wang YL et al.: PD-1 expression by macrophages plays a pathologic role in altering microbial clearance and the innate infammatory response to sepsis. Proc Natl Acad. Sci. USA 106, 6303-6308 (2009).
79. Brahmamdam P, Inoue S, Unsinger J et al.: Delayed administration of anti-PD-1 antibody reverses immune dysfunction and improves survival during sepsis. J. Leukocyte Biol. 88, 233-240 (2010).
80. Hotchkiss RS, Opal S: Immunotherapy for sepsis-a new approach against an ancient foe. N. Engl. J. Med. 363, 87-89 (2010).